RELEVIUM TECHNOLOGIES INC. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “
Company”
or “
Relevium”), a company
operating in the Personal Protective Equipment
(“
PPE) sector, is pleased to announce today it has
entered into a non-binding term sheet (“
Term
Sheet”) in respect of a proposed acquisition of all the
issued and outstanding shares of
MED PPE CANADA
INC. (“
Med PPE”), a distributor of
medical equipment, purification systems, and PPE and supplies to
the Canadian market.
MED PPE CANADA INC.
Med PPE is a privately held, Edmonton-based
corporation formed in April 2020 to focus on global market demand
and supply of PPE products. Med PPE is a fully licensed distributor
of PPE equipment as well as purification systems, and is currently
pursuing all forms of PPE, utilizing multiple international
resources and procurement opportunities. Med PPE has established a
fully licensed facility to operate within the PPE sector, allowing
direct selling to all levels of government, professional and
medical institutions in Canada.
STRATEGIC SYNERGY
The accretive acquisition of MED PPE will
greatly strengthen Relevium’s existing PPE business, which has
primarily focused on business supply channels into the North
American market. The combined business will allow Relevium to
aggressively pursue and secure government and institutional PPE
tenders through its established state-of-the-art logistics
platform, as well as utilization and distribution of air
purification and disinfection technologies. MED PPE, along with
Relevium and its partners, will allow for greater cross-border
North American business opportunities, and leverage strategic sales
and marketing channels.
Aurelio Useche, CEO of Relevium stated: “The
addition of MED PPE and its team to Relevium is a significant step
to validating our current business strategy in providing a
“stable” and “trusted” source of
essential medical supplies and PPE to the North American markets.
We are excited to work with Mr. Booth and his team of
professionals, and we look forward to the successful completion of
this transaction.”
Terry Booth, CEO of MED PPE stated: “We are
excited to join forces with Relevium and to expand our combined
business beyond the scope of the ongoing pandemic. As the new
business combination continues to execute on plan, we are ready to
provide solid and predictable sourcing for various medical
supplies, both to the Canadian market, as well as expansion and
support to ongoing efforts in the United States and beyond.” Booth
added: “We expect that with Relevium and our science teams our
penetration into air quality system markets will have a significant
impact on reducing the risk of any viral disease spread and result
in shareholder value.”
Foundation Markets Inc., a Toronto based
boutique investment bank and Exempt Market Dealer is acting as
advisor to the Company on this transaction.
TRANSACTION TERMS
Under the terms of the proposed transaction the
Company would acquire all of the outstanding shares of Med PPE for
an initial consideration of $2,400,000 payable through the issuance
of 120,000,000 common shares in the capital of the Company on
closing and an earnout purchase price of up to
$8,566,000, payable upon the achievement of certain Revenue and
EBITDA targets for the Med PPE business for the 2021 and 2022
calendar years (the "Earnout Payments").
Under the proposed terms, the vendors of the Med
PPE shares would receive (i) a $500,000 Earnout Payment if the Med
PPE revenue for 2021 is $7,200,000 and the amount of this Earnout
Payment would increase by $0.16 for every $1 of revenue exceeding
the $7,200,000 target, to a maximum of $1,000,000; (ii) a $375,000
Earnout Payment if the Med PPE EBITDA margin is equal to or greater
than 5% for 2021 and the amount of this Earnout Payment would
increase by $150,000 for every 1% of EBITDA margin above 5%, to a
maximum of $1,500,000; (iii) a $1,000,000 Earnout Payment if the
Med PPE revenue for 2022 is $9,800,000 and the amount of this
Earnout Payment will increase or decrease by $0.10 for every $1 of
revenue above or below the $9,800,000 target, to a maximum of
$2,000,000; and (iv) a $500,000 Earnout Payment if the Med PPE
EBITDA for 2022 is $300,000 and the amount of this Earnout Payment
would increase or decrease by $3.33 for every $1 of EBITDA above or
below the $300,000 target, to a maximum of $1,666,000 and with no
Earnout Payment being paid for this item if EBITDA for 2022 is less
than $225,000.
The Earnout Payments would be payable in common
shares of the Company with the number of shares to be issued being
calculated based on the volume weighted average trading price of
the common shares of the Company for the 10 days preceding the date
of issuance.
Completion of the transaction is subject to
customary closing conditions including the completion of due
diligence, negotiation of definitive agreements and receipt of all
necessary regulatory approvals including, without limitation,
approval of the TSX Venture Exchange. There is no guarantee that
the proposed transaction will be completed on the terms set forth
herein or at all.
About Relevium Technologies
Relevium Technologies Inc., is
a publicly traded company, focused on international procurement,
logistics, and delivery of PPE into the North American marketplace.
Utilizing trusted vendors and suppliers, and integrating a
comprehensive, state-of-the-art supply chain, Artificial
Intelligence, and Blockchain technology, enables a highly secure
and compliant platform for delivery of PPE equipment to
governments, hospitals, foundations, and various institutions.
Neither the TSX
Venture Exchange
nor its Regulation
Services Provider (as
that term is
defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy
or accuracy of this release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future
performance, including the timing and completion of the proposed
acquisition and the terms thereof, are forward-looking statements
and contain forward-looking information. Generally, forward-
looking statements and information can be identified by the use of
forward-looking terminology such as "intends" or "anticipates", or
variations of such words and phrases or statements that certain
actions, events or results "may", "could", "should", "would" or
"occur".
Forward-looking statements are based on certain
material assumptions and analysis made by the Company and the
opinions and estimates of management as of the date of this press
release, including the assumptions that the Company will be able to
satisfy the conditions to complete the proposed acquisition.
These forward-looking statements are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information. Important factors that may cause
actual results to vary, include, without limitation, the risk that
the Company is unable to satisfy the conditions of closing the
proposed acquisition including receipt of all necessary regulatory
approvals.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbour.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687
RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.comWebsite: www.releviumtechnologies.comLike
us on FacebookFollow us on TwitterFollow us on LinkedIn
Relevium Technologies (TSXV:RLV)
過去 株価チャート
から 10 2024 まで 11 2024
Relevium Technologies (TSXV:RLV)
過去 株価チャート
から 11 2023 まで 11 2024